Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: Chemoradiotherapy; Drug: Ipilimumab; Drug: Nivolumab Sponsors: Medical University of Vienna; Bristol-Myers Squibb Not yet recruiting
Abstract OBJECTIVE: In selected rectal cancer patients with residual local disease following neoadjuvant chemoradiation (CRT) and the preference of an organ preservation pathway, additional treatment with dose escalation by endoluminal radiotherapy (RT) may ultimately result in a clinical complete response. To date, the widespread introduction of selective endoluminal radiation techniques is hampered by a lack of evidence-based guidelines that describe the radiation treatment volume in relation to the residual tumor mass. In order to convert an incomplete response into a complete one with additional treatment such...
Conclusion: The SIB-VMAT technique is effective and safe for irradiating locally advanced rectal cancer. Its effectiveness is expressed in higher clinical and pathological complete response rates and safety with the same rates of acute toxicity. PMID: 31651118 [PubMed - in process]
Conclusion: The strategy proposed seemed safe and effective, resulting in radical treatment and persistence of regular menstrual period. Further studies are needed. PMID: 31650042 [PubMed]
Conditions: Rectal Neoplasms Malignant; Rectum Carcinoma; Rectal Cancer Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Radiation: Radiotherapy; Procedure: Rectal cancer surgery Sponsor: Blokhin's Russian Cancer Research Center Enrolling by invitation
CONCLUSION: Patients with a pCR in whom an anastomosis was created were at increased risk of developing an anastomotic leak. PMID: 31625143 [PubMed - as supplied by publisher]